Merck an Unhealthy Stock to Sell
Merck & Co. (NYSE: MRK ) - Following a major advance in the stock market, investors should review their holdings and cull out non-performers that are inhibiting overall portfolio profits. Despite being a global health care company, MRK is one of those stocks to sell.
Not only is the stock still in a bear trend, but the past five years have averaged a negative earnings growth of about 33%, and current profit margins are at a mere 1.87% in an industry that averages in the teens.
About a month ago, TD Ameritrade cut their opinion of MRK to "reduce," and we agree. Even though the dividend yield is at 4.7%, there is no assurance that it will stay at that level, and an increase in bond interest rates would bring in sellers who have held this stock as a "bond substitute."
Sell MRK at the market.
If you have questions or comments for Sam Collins, please e-mail him at firstname.lastname@example.org .